Dr. David F. Claxton, MD
- Medicare services, 2024
- 60
- Medicare patients, 2024
- 17
- Part D claims, 2024
- 31
- Publications
- 107
- Clinical trials
- 8
- Practice address
- 555 N Duke St, Lancaster, PA 17602
- Practice phone
- Call (717) 544-5511
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Lancaster General Hospital
Lancaster, Pennsylvania
Find Dr. Claxton's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. David F. Claxton is a hematologist and oncologist in Lancaster, Pennsylvania
Dr. Claxton practices at Lancaster General Hospital in Lancaster, Pennsylvania.
Dr. Claxton's NPI, 1073562351, was assigned on May 6, 2006. Dr. Claxton holds Pennsylvania license MD070865L.
- NPI
- 1073562351NPI Registry (opens in a new tab)
- NPI enumeration date
- May 6, 2006
- NPI status
- Active
- Practice phone
- (717) 544-5511
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 74
- Medical school graduation
- 1978
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Practice Data
Dr. David F. Claxton practices at Lancaster General Hospital in Lancaster, Pennsylvania
Dr. Claxton's primary practice is Lancaster General Hospital, at 555 N Duke St, Lancaster, PA 17602 in Lancaster County. The practice phone is (717) 544-5511.
- Lancaster General Hospital555 N Duke St, Lancaster, PA 17602 · Lancaster CountyPhone(717) 544-5511
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dr. David F. Claxton is affiliated with 2 sites of care and 2 medical groups
Dr. Claxton's primary practice is Lancaster General Hospital in Lancaster, Pennsylvania. Dr. Claxton is also affiliated with Penn State Health Milton S. Hershey Medical Center. The medical group on file is Penn State Health Milton S. Hershey Medical Center. Dmand AI also links Dr. Claxton to 1 more medical group, named with a free account.
Sources: NPPES NPI Registry (CMS); Dmand AI Practice Data; Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. David F. Claxton's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Claxton practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Lancaster General Hospital | Available with a free account |
| +1 more site and 1 medical group | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. David F. Claxton is one of 645 hematologists and oncologists in Pennsylvania
Hematology and oncology is Dr. Claxton's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Claxton is licensed in Pennsylvania.
Specialties and state licenses
- Hematology and oncology, PennsylvaniaPrimary
Hematologists and oncologists near Dr. Claxton
Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. David F. Claxton billed Medicare for 60 services in 2024
CMS data shows 60 Medicare services from Dr. Claxton across 2 procedure codes in 2024, for 17 Medicare patients. Medicare paid $4,362 for them. Every service was in a facility, such as a hospital, rather than an office.
Dr. Claxton's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 1772024: 6066%
Dr. Claxton compared with the Pennsylvania median for hematologists and oncologists, 2024
- Dr. Claxton
- Pennsylvania median
- Medicare services
- 60vs 65491% below
- Medicare patients
- 17vs 22793% below
- Part D claims
- 98vs 39375% below
Medians across 600 hematologists and oncologists in Pennsylvania with Dmand AI profiles that report each measure.
Dr. Claxton's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Claxton?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Claxton and other hematologists and oncologists in Pennsylvania.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. David F. Claxton treated 17 Medicare patients in 2024, average age 68
CMS counts 17 Medicare patients who saw Dr. Claxton in 2024. The largest group is 85 and over, with 0 patients. 75% of them have high blood pressure, and 71% have high cholesterol. Their average risk score is 3.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Claxton's median patient age at 75, with 0% women.
Dr. Claxton's Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Chronic conditions among Dr. Claxton's Medicare patients, 2024
- High blood pressure75%
- High cholesterol71%
Share of Medicare patients with each condition. A patient can have several.
Dr. Claxton's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 75
Patient panel by sex, all payers
- Women0%
- Men100%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. David F. Claxton wrote 31 Medicare Part D claims in 2024
In 2024, Dr. Claxton wrote 31 Medicare Part D claims. 52% of them were for generic drugs. They cover 8 drugs, with $381,508 in total drug cost. In 2022, CMS named 502 claims across 28 drugs.
Dr. Claxton's Part D claims by kind of drug, 2024
- Generic16 claims52%
- Brand-name15 claims48%
Dr. Claxton's most prescribed drugs by claims, 2023
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2022 to 2023
- 2022
- 2023
- Claims for drugs CMS names
- 2022: 5022023: 9880%
Drugs named by CMS: 8 in 2023, 28 in 2022.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. David F. Claxton scored 79 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Claxton for performance year 2024, reported as part of a group.
Dr. Claxton's MIPS scores, performance year 2024
- 79of 100Final score
- 56.7of 100Quality
- 100of 100Promoting Interoperability
- 40of 100Improvement Activities
- 75of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Source: Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. David F. Claxton has 107 publications on record
Dmand AI links 107 papers to Dr. Claxton, published from 2011 to 2025. 2018 was the busiest year, with 14. The most frequent topics are Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation and Antineoplastic Agents. Dr. Claxton has published most often in Blood Adv. Dr. Claxton's most frequent co-authors are Thomas P. Loughran, MD, Shin Mineishi, MD and Seema Girish Naik, MD.
Dr. Claxton's papers by year, 2016 to 2025
Topics Dr. Claxton writes about most
- Leukemia, Myeloid, Acute
- Hematopoietic Stem Cell Transplantation
- Antineoplastic Agents
- Cell Line, Tumor
- Apoptosis
- Transplantation, Homologous
- Cyclophosphamide
- Graft vs Host Disease
Dr. Claxton's most frequent co-authors
- Thomas P. Loughran, MD24 shared papers
- Shin Mineishi, MD22 shared papers
- Seema Girish Naik, MD16 shared papers
Recent publications by Dr. Claxton
See who Dr. Claxton researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Claxton works with, so you can find a warm path to the right hematologists and oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. David F. Claxton has worked on 8 clinical trials
Dmand AI links Dr. Claxton to 8 clinical trials, 3 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Burkitt Lymphoma. ECOG-ACRIN Cancer Research Group sponsors the most, 2. Open Payments lists research payments to Dr. Claxton that name 1 trial.
Clinical trials with Dr. Claxton by phase
- NonePhase 1: no trials
- 1Phase 1/2: 1 trial
- 2Phase 2: 2 trials
- 3Phase 3: 3 trials
- NonePhase 4: no trials
Conditions in Dr. Claxton's trials
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
- Burkitt Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Megakaryoblastic, Acute
Investigators on the most trials with Dr. Claxton
- Stephen Anthony Strickland, MD4 shared trials
- Jessica Kaplan Altman, MD3 shared trials
- Ehab L. Atallah, MD3 shared trials
Recent clinical trials with Dr. Claxton
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia (opens in a new tab)
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (opens in a new tab)
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia (opens in a new tab)
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (opens in a new tab)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. David F. Claxton received $1,844 in industry payments from 2016 to 2021
CMS Open Payments shows 24 general payments to Dr. Claxton from 13 drug and device companies from 2016 to 2021. Food and beverage make up the largest share, 67% of the total. Pfizer Inc. paid the most, $242. It also lists 4 research payments totaling $1,970 in 2016, naming 1 clinical trial.
General payments to Dr. Claxton by program year, 2016 to 2021
General payments to Dr. Claxton by kind, 2016 to 2021
- Food and beverage$1,24167%
- Education$60333%
Companies that paid Dr. Claxton the most, 2016 to 2021
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. David F. Claxton's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data |
| Primary practice, affiliations and health system | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice DataDmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. David F. Claxton
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. David F. Claxton's NPI number?
Dr. David F. Claxton's NPI number is 1073562351. It was assigned on May 6, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. David F. Claxton?
Dr. David F. Claxton is a hematologist and oncologist in Lancaster, Pennsylvania. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).
Where does Dr. David F. Claxton practice?
Dr. Claxton practices at 555 N Duke St, Lancaster, PA 17602. Dr. Claxton's primary practice is Lancaster General Hospital in Lancaster, Pennsylvania. Dmand AI also links Dr. Claxton to 1 medical group.
What is Dr. David F. Claxton's office phone number?
The practice phone on file for Dr. Claxton is (717) 544-5511.
What is Dr. David F. Claxton's medical license number?
Dr. Claxton holds Pennsylvania license MD070865L.
Which hospitals is Dr. David F. Claxton affiliated with?
Dr. Claxton is affiliated with Penn State Health Milton S. Hershey Medical Center.
What medical group is Dr. David F. Claxton part of?
Dr. Claxton is linked to Penn State Health Milton S. Hershey Medical Center. Dmand AI links Dr. Claxton to 1 more medical group.
Does Dr. David F. Claxton accept Medicare?
Yes. CMS data shows Dr. Claxton billed Medicare for 60 services in 2024.
What is Dr. David F. Claxton's MIPS score?
Dr. Claxton's MIPS final score for performance year 2024 is 79 out of 100, reported as part of a group.
How many Medicare patients does Dr. David F. Claxton see?
CMS counts 17 Medicare patients who saw Dr. Claxton in 2024, with an average age of 68.
Show 6 more questionsShow fewer questions
What services does Dr. David F. Claxton bill to Medicare?
In 2024, Dr. Claxton's most billed Medicare services were hospital inpatient care (99232) and hospital inpatient care (99233).
What drugs does Dr. David F. Claxton prescribe most?
In 2023 Medicare Part D data, Dr. Claxton's most prescribed drugs by claims were Sprycel, Lidocaine and Mycophenolate Mofetil.
Has Dr. David F. Claxton received payments from drug or device companies?
CMS Open Payments shows $1,844 in general payments to Dr. Claxton from 13 companies from 2016 to 2021. The largest total came from Pfizer Inc.
How long has Dr. David F. Claxton been practicing?
Dr. Claxton graduated from medical school in 1978, 48 years ago.
Does Dr. David F. Claxton do research?
Dmand AI links 107 publications to Dr. Claxton, published from 2011 to 2025. Dr. Claxton has worked on 8 clinical trials.
Who does Dr. David F. Claxton publish with?
Dr. Claxton's most frequent co-authors are Thomas P. Loughran, MD (24 shared papers), Shin Mineishi, MD (22 shared papers) and Seema Girish Naik, MD (16 shared papers).
Selling to hematology and oncology practices?
See hematologists and oncologists in Pennsylvania by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card